Johnson & Johnson's Janssen Pharmaceuticals offshoot has told analysts it plans to seek regulatory approval for more than 10 new drugs up to 2019, each with the potential to generate at least $1 billion annual sales.

This would come in addition to more than 40 line extensions of existing and new medicines. The US pharmaceutical major said it expects top-line growth above the industry average through 2019.

Janssen's portfolio focuses on the five core therapeutic areas: immunology; infectious diseases & vaccines; neuroscience; cardiovascular & metabolism and oncology.

Since 2009, the drugmaker has launched 14 new products, seven of which are expected to achieve blockbuster status this year, with sales of more than $1 billion.

Late stage products in the Janssen pipeline include daratumumab for multiple myeloma, sirukumab for rheumatoid arthritis, guselkumab for psoriasis, JNJ-927 (ARN0509) for pre-metastatic prostate cancer, imetelstat for myelofibrosis, JNJ-493 for urothelial cancer, esketamine for treatment-resistant depression and AL-8176 for hepatitis C.

In February of this year, the company announced the launch of three new research platforms focused on disease prevention, disease intervention and the microbiome, with the intent to potentially change the way diseases are managed.